Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8NI22
UPID:
MCFD2_HUMAN
Alternative names:
Neural stem cell-derived neuronal survival protein
Alternative UPACC:
Q8NI22; A8K7W2; D6W5A9; E9PD95; Q53SS3; Q68D61; Q8N3M5
Background:
Multiple coagulation factor deficiency protein 2 (MCFD2), also known as Neural stem cell-derived neuronal survival protein, plays a pivotal role in blood coagulation. It is part of the MCFD2-LMAN1 complex, a specific cargo receptor crucial for the ER-to-Golgi transport of selected proteins, including coagulation factors.
Therapeutic significance:
MCFD2 is directly linked to Factor V and factor VIII combined deficiency 2, a blood coagulation disorder marked by bleeding symptoms. Understanding the role of MCFD2 could open doors to potential therapeutic strategies for treating this deficiency.